Patient preferences for different severities of and treatments for overactive bladder

Female Pelvic Medicine and Reconstructive Surgery

Volumn 17, Issue 4, 2011, Pages 184-189

  Wu, Jennifer M ^a   Fulton, Rebekah G ^a   Amundsen, Cindy L ^a   Knight, Sharon K ^b   Kuppermann, Miriam ^b,c  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Overactive bladder; Patient preferences; Urge urinary incontinence; Utility

Indexed keywords

UROLOGY;

ACADEMIC INSTITUTIONS; ADVERSE EFFECT; BOTULINUM; BOTULINUM TOXIN INJECTION; INVASIVENESS; NEUROMODULATION; OVERACTIVE BLADDER; PATIENT PREFERENCES; PREFERENCE ELICITATION; QUALITY OF LIFE; QUANTITATIVE DATA; URINARY INCONTINENCE; UTILITY;

PATIENT TREATMENT;

EID: 80053043440     PISSN: 21518378     EISSN: None     Source Type: Journal    
DOI: 10.1097/SPV.0b013e318223c8ad     Document Type: Article

References (24)

1. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20: 327-336. (Pubitemid 44175300)
2. Hu TW, Wagner TH, Bentkover JD, et al. Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology 2004;63:461-465.
3. National Institutes of Health. Disease-specific estimates of direct and indirect costs of illness and NIH support. Fiscal year 2000. Available at: http://ospp.od.nih.gov/ecostudies/COIreportweb.htm. Accessed July 1, 2010.
4. Abrams P, Kelleher CJ, Kerr LA, et al. Overactive bladder significantly affects quality of life. Am J Manag Care 2000;6:S580-S590. (Pubitemid 30649379)
5. Brown JS, Subak LL, Gras J, et al. Urge incontinence: the patient's perspective. J Womens Health 1998;7:1263-1269.
6. Hagglund D, Walker-Engstrom ML, Larsson G, et al. Changes in urinary incontinence and quality of life after four years. A population-based study of women aged 22-50 years. Scand J Prim Health Care 2004;22:112-117. (Pubitemid 38828762)
7. Liberman JN, Hunt TL, Stewart WF, et al. Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. Urology 2001;57:1044-1050. (Pubitemid 32455563)
8. Bennett KJ, Torrance GW. Measuring health state preferences and utilities: rating scale, time trade-off, and standard gamble techniques. In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. New York, NY: Raven-Lippincott; 1996:253-265.
9. Getsios D, El-Hadi W, Caro I, et al. Pharmacological management of overactive bladder : a systematic and critical review of published economic evaluations. Pharmacoeconomics 2005;23:995-1006. (Pubitemid 41603433)
10. Coyne K, Revicki D, Hunt T, et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 2002;11:563-574. (Pubitemid 34876130)
11. Kelleher CJ, Cardozo LD, Khullar V, et al. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol 1997;104:1374-1379. (Pubitemid 27517634)
12. Lubeck DP, Prebil LA, Peeples P, et al. A health related quality of life measure for use in patients with urge urinary incontinence: a validation study. Qual Life Res 1999;8:337-344. (Pubitemid 29369638)
13. Froberg DG, Kane RL. Methodology for measuring health-state preferences. II: Scaling methods. J Clin Epidemiol 1989;42:459-471. (Pubitemid 19165912)
14. Green C, Brazier J, Deverill M. Valuing health-related quality of life. A review of health state valuation techniques. Pharmacoeconomics 2000;17:151-165. (Pubitemid 30148812)
15. Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
16. Blumenschein K, Johannesson M. Relationship between quality of life instruments, health state utilities, and willingness to pay in patients with asthma. Ann Allergy Asthma Immunol 1998;80: 189-194. (Pubitemid 28103154)
17. Read JL, Quinn RJ, Berwick DM, et al. Preferences for health outcomes. Comparison of assessment methods. Med Decis Making 1984;4: 315-329. (Pubitemid 15167607)
18. Sano M, Albert SM, Tractenberg RE, et al. Developing utilities for stages of Alzheimer's disease using the Clinical Dementia Rating. J Mental Health Aging. 1999;5:59-68. (Pubitemid 29235118)
19. Smith DS, Krygiel J, Nease RF Jr, et al. Patient preferences for outcomes associated with surgical management of prostate cancer. J Urol 2002;167:2117-2122. (Pubitemid 34309678)
20. Dedhia RC, Calhoun E, McVary KT. Impact of phytotherapy on utility scores for 5 benign prostatic hyperplasia/lower urinary tract symptoms health states. J Urol 2008;179:220-225. (Pubitemid 350216743)
21. Schulz MW, Chen J, Woo HH, et al. A comparison of techniques for eliciting patient preferences in patients with benign prostatic hyperplasia. J Urol 2002;168:155-159. (Pubitemid 34640805)
22. Mittmann N, Trakas K, Risebrough N, et al. Utility scores for chronic conditions in a community-dwelling population. Pharmacoeconomics 1999;15:369-376. (Pubitemid 29190028)
23. Subak LL, Brown JS, Kraus SR, et al. The "costs" of urinary incontinence for women. Obstet Gynecol 2006;107:908-916.
24. Torrance GW. Preferences for health states: a review of measurement methods. Mead Johnson Symp Perinat Dev Med 1982;37-45.